More recently, the PARP1 inhibitor (PARPi) Olaparib/Lynparza has been incorporated into treatment regimens for breast, prostate and ovarian cancer, including strategies delivering chemoradiosensitisation of BRCA-deficient tumours, and is currently undergoing clinical trial assessment for glioblastoma [35,36,37,38]. Here, PARP1 is linked to ovarian carcinoma.